Trexquant Investment’s Pacific Biosciences PACB Stock Holding History

Trexquant Investment’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-453,524	Closed	-$2.63M	–	1642
2022 Q3	$2.63M	Buy	453,524 +387,164	+583%	+$2.22M	0.09%	277
2022 Q2	$293K	Buy	+66,360	New	+$403K	0.01%	1136
2021 Q2	–	Sell	-45,633	Closed	-$1.52M	–	1393
2021 Q1	$1.52M	Buy	45,633 +21,879	+92%	+$766K	0.14%	191
2020 Q4	$616K	Buy	+23,754	New	+$404K	0.07%	379
2016 Q4	–	Sell	-37,342	Closed	-$335K	–	1099
2016 Q3	$335K	Buy	+37,342	New	+$312K	0.07%	436
2015 Q3	–	Sell	-81,300	Closed	-$468K	–	1207
2015 Q2	$468K	Buy	81,300 +64,500	+384%	+$373K	0.05%	646
2015 Q1	$98K	Buy	+16,800	New	+$116K	0.01%	954

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Trexquant Investment's PACB Position: Q4 2022 in Review

Trexquant Investment sold out of Pacific Biosciences (PACB) in Q4 2022, closing a stake of 453,524 shares — an estimated $2.63M sold.

Trexquant Investment first reported a position in PACB in Q1 2015 and held it in 7 quarters. The position peaked at $2.63M in Q3 2022. 235 funds tracked by Wall St. Rank hold PACB as of Q4 2022.

Trexquant Investment reported no remaining Pacific Biosciences position as of Q4 2022 after selling out during the quarter.
Trexquant Investment sold 453,524 Pacific Biosciences shares in Q4 2022, an estimated $2.63M.
Trexquant Investment first reported a position in Pacific Biosciences in Q1 2015 and held it in 7 quarters.
Trexquant Investment's Pacific Biosciences position peaked at $2.63M in Q3 2022.
235 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2022.

Based on Trexquant Investment's 13F filing for Q4 2022, filed 13 Feb 2023.